Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-04-09

Clinical Trial Update: Postmarketing Clinical Study on AO-128 [Phase 4]

View source ↗

Summary

Takeda's postmarketing Phase 4 study of AO-128 in impaired glucose tolerance has completed, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AO-128

Snippet

Sponsor: Takeda | Conditions: Impaired Glucose Tolerance (IGT) | Phase 4 | Status: COMPLETED | Results posted: 2015-04-09